# PSMA-DC (NCT05939414)

> An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05939414
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Oligometastatic Prostate Cancer (OMPC)
- Interventions: AAA617; piflufolastat (18F); gallium (68Ga) gozetotide (25μg)
- Enrollment: 450
- Primary outcome: Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)

## Commentary we found

- YouTube: 15
- Podcasts: 9
- X threads: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=psma-dc-nct05939414

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05939414", "email": "<work email>"}; the inbox owner confirms by the emailed link.